Finding an effective treatment for Alzheimer’s has been a significant focus of research for many years, and two very promising drugs have recently been granted FDA approval. While these therapies, Lecanemab and Donanemab, have shown some very encouraging results, they have not been without complication. A very different approach to pharmaceuticals, Silverado’s holistic, lifestyle-based Nexus program has produced measured results that show it to be an effective alternative for individuals battling Alzheimer’s.
Before delving into why the Nexus program may provide superior benefits, it is important to first understand Lecanemab and Donanemab. Both are monoclonal antibodies designed to target and remove the beta-amyloid plaques in the brain believed to be responsible for Alzheimer’s disease. While they have shown promising results in reducing these plaques and potentially slowing cognitive decline, they do
have several limitations:
- Side Effects: Lecanemab and Donanemab may cause side effects such as headaches, confusion, and risks of brain swelling or microbleeds. For some patients, these side effects can be severe, posing additional health challenges.
- Accessibility and Cost: These treatments require regular, expensive intravenous infusions, making them less accessible to a broad population of patients.
- Individual Variability: These drugs have been found to work better in some people than in others. Not all patients with Alzheimer’s have a significant build-up of beta-amyloid, meaning these treatments may be ineffective for a subset of patients.
Silverado’s Nexus program adopts a different approach to tackling Alzheimer’s disease. It focuses on a life-enriching, evidence-based lifestyle program that enhances cognitive function, promotes purposeful, social engagement and encourages physical activity. Participants in this internationally recognized brain
health program have shown a statistically significant 60% improvement in cognition when compared to those without such treatment. Nexus, is therefore a preferred alternative to monoclonal antibody treatments because of its:
- Holistic Approach: Nexus is centered around a comprehensive approach addressing multiple facets of one’s well-being. This includes five areas of focus: physical exercise, stress reduction, cognitive exercise, purposeful social engagement and psychosocial support within a specialized social environment. This well-rounded approach targets not just the symptoms but also the overall well-being of the person.
- Personalization: Unlike monoclonal antibody treatments, which may not work for everyone, the Nexus program can be personalized to each individual’s needs and capabilities. It ensures that all participants receive the care and stimulation best suited to them, maximizing the potential benefits.
- Fewer Side Effects: The Nexus program, being non-pharmacological, carries minimal risk of physical side effects compared to drug treatments.
- Affordability and Accessibility: The Nexus program is designed to be affordable and accessible, without the need for specialized medical equipment or expensive drugs.
- Enhanced Quality of Life: The Nexus program aims not just to slow cognitive decline but also to enhance quality of life. Social engagement, mental stimulation, and physical activity all play essential roles in overall well-being and happiness, beyond just tackling the disease symptoms.
While Lecanemab and Donanemab represent significant strides in Alzheimer’s disease treatment, they are not without limitations. Silverado’s Nexus program offers an innovative alternative that addresses these limitations. Its comprehensive, personalized and holistic approach not only assists in combating cognitive decline, but also significantly enhances the overall quality of life of Alzheimer’s patients, making it a compelling choice for many
